JP2021059555A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021059555A5 JP2021059555A5 JP2020203413A JP2020203413A JP2021059555A5 JP 2021059555 A5 JP2021059555 A5 JP 2021059555A5 JP 2020203413 A JP2020203413 A JP 2020203413A JP 2020203413 A JP2020203413 A JP 2020203413A JP 2021059555 A5 JP2021059555 A5 JP 2021059555A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- transfection complex
- complex according
- bromide
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000001890 transfection Methods 0.000 claims 14
- 229910052757 nitrogen Inorganic materials 0.000 claims 13
- 150000002632 lipids Chemical class 0.000 claims 8
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 6
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 6
- 230000008685 targeting Effects 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims 4
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- -1 (9-octadecenyloxy)- Chemical class 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 3
- BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 claims 3
- KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 claims 3
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 125000002091 cationic group Chemical group 0.000 claims 3
- 235000012000 cholesterol Nutrition 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims 2
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 claims 2
- XULFJDKZVHTRLG-JDVCJPALSA-N DOSPA trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCNC(=O)C(CCCNCCCN)NCCCN)OCCCCCCCC\C=C/CCCCCCCC XULFJDKZVHTRLG-JDVCJPALSA-N 0.000 claims 2
- KLFKZIQAIPDJCW-HTIIIDOHSA-N Dipalmitoylphosphatidylserine Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCC KLFKZIQAIPDJCW-HTIIIDOHSA-N 0.000 claims 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims 2
- 125000000656 azaniumyl group Chemical group [H][N+]([H])([H])[*] 0.000 claims 2
- 230000000975 bioactive effect Effects 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 claims 1
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 claims 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims 1
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 claims 1
- WALUVDCNGPQPOD-UHFFFAOYSA-M 2,3-di(tetradecoxy)propyl-(2-hydroxyethyl)-dimethylazanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCOCC(C[N+](C)(C)CCO)OCCCCCCCCCCCCCC WALUVDCNGPQPOD-UHFFFAOYSA-M 0.000 claims 1
- 125000005999 2-bromoethyl group Chemical group 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- UVDZEXDYRJVBEI-UHFFFAOYSA-N CCCCCCCCCCCCCCCCCCNCCCCCCCCCCCCCCCCCC.NCCCNCCCCNCCCN(C(CN)=O)C(O)=O Chemical compound CCCCCCCCCCCCCCCCCCNCCCCCCCCCCCCCCCCCC.NCCCNCCCCNCCCN(C(CN)=O)C(O)=O UVDZEXDYRJVBEI-UHFFFAOYSA-N 0.000 claims 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims 1
- 241000755712 Diores Species 0.000 claims 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 1
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 claims 1
- 108010079855 Peptide Aptamers Proteins 0.000 claims 1
- 108091027967 Small hairpin RNA Proteins 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 108091060271 Small temporal RNA Proteins 0.000 claims 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 1
- HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 claims 1
- 125000002015 acyclic group Chemical group 0.000 claims 1
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 150000003863 ammonium salts Chemical class 0.000 claims 1
- VJLOFJZWUDZJBX-UHFFFAOYSA-N bis(2-hydroxyethyl)azanium;chloride Chemical compound [Cl-].OCC[NH2+]CCO VJLOFJZWUDZJBX-UHFFFAOYSA-N 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 229940106189 ceramide Drugs 0.000 claims 1
- 150000001783 ceramides Chemical class 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- UMGXUWVIJIQANV-UHFFFAOYSA-M didecyl(dimethyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC UMGXUWVIJIQANV-UHFFFAOYSA-M 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- OSZGJYNGVGNCGA-IZNNDHRXSA-N dihexadecyl-methyl-[(2r,3s,4r)-2,3,4,5-tetrahydroxypentyl]azanium Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C[C@@H](O)[C@H](O)[C@H](O)CO)CCCCCCCCCCCCCCCC OSZGJYNGVGNCGA-IZNNDHRXSA-N 0.000 claims 1
- OSZGJYNGVGNCGA-YXWIYCFASA-N dihexadecyl-methyl-[(2s,3r,4r)-2,3,4,5-tetrahydroxypentyl]azanium Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C[C@H](O)[C@@H](O)[C@H](O)CO)CCCCCCCCCCCCCCCC OSZGJYNGVGNCGA-YXWIYCFASA-N 0.000 claims 1
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 claims 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 1
- 150000002314 glycerols Chemical class 0.000 claims 1
- MVYQJCPZZBFMLF-UHFFFAOYSA-N hydron;propan-1-amine;bromide Chemical compound [Br-].CCC[NH3+] MVYQJCPZZBFMLF-UHFFFAOYSA-N 0.000 claims 1
- 229940067606 lecithin Drugs 0.000 claims 1
- 239000000787 lecithin Substances 0.000 claims 1
- 235000010445 lecithin Nutrition 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 108091070501 miRNA Proteins 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- DAZXVJBJRMWXJP-UHFFFAOYSA-N n,n-dimethylethylamine Chemical compound CCN(C)C DAZXVJBJRMWXJP-UHFFFAOYSA-N 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 108091008104 nucleic acid aptamers Proteins 0.000 claims 1
- 230000030648 nucleus localization Effects 0.000 claims 1
- 150000008105 phosphatidylcholines Chemical class 0.000 claims 1
- 229940067605 phosphatidylethanolamines Drugs 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 239000002924 silencing RNA Substances 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 150000003408 sphingolipids Chemical class 0.000 claims 1
- 0 CNCC(CO)NC*CCCCC=*CC* Chemical compound CNCC(CO)NC*CCCCC=*CC* 0.000 description 6
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022141466A JP7512335B2 (ja) | 2010-11-15 | 2022-09-06 | アミン含有トランスフェクション試薬ならびにそれを生成および使用するための方法 |
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41390510P | 2010-11-15 | 2010-11-15 | |
| US61/413,905 | 2010-11-15 | ||
| US201161437503P | 2011-01-28 | 2011-01-28 | |
| US61/437,503 | 2011-01-28 | ||
| US201161438903P | 2011-02-02 | 2011-02-02 | |
| US61/438,903 | 2011-02-02 | ||
| US201161543242P | 2011-10-04 | 2011-10-04 | |
| US61/543,242 | 2011-10-04 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018146564A Division JP6807900B2 (ja) | 2010-11-15 | 2018-08-03 | アミン含有トランスフェクション試薬ならびにそれを生成および使用するための方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022141466A Division JP7512335B2 (ja) | 2010-11-15 | 2022-09-06 | アミン含有トランスフェクション試薬ならびにそれを生成および使用するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021059555A JP2021059555A (ja) | 2021-04-15 |
| JP2021059555A5 true JP2021059555A5 (https=) | 2021-08-05 |
| JP7138692B2 JP7138692B2 (ja) | 2022-09-16 |
Family
ID=45217672
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013539959A Pending JP2014508102A (ja) | 2010-11-15 | 2011-11-15 | アミン含有トランスフェクション試薬ならびにそれを生成および使用するための方法 |
| JP2016183855A Pending JP2017031186A (ja) | 2010-11-15 | 2016-09-21 | アミン含有トランスフェクション試薬ならびにそれを生成および使用するための方法 |
| JP2017248675A Active JP6383480B2 (ja) | 2010-11-15 | 2017-12-26 | アミン含有トランスフェクション試薬ならびにそれを生成および使用するための方法 |
| JP2018146564A Active JP6807900B2 (ja) | 2010-11-15 | 2018-08-03 | アミン含有トランスフェクション試薬ならびにそれを生成および使用するための方法 |
| JP2020203413A Active JP7138692B2 (ja) | 2010-11-15 | 2020-12-08 | アミン含有トランスフェクション試薬ならびにそれを生成および使用するための方法 |
| JP2022141466A Active JP7512335B2 (ja) | 2010-11-15 | 2022-09-06 | アミン含有トランスフェクション試薬ならびにそれを生成および使用するための方法 |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013539959A Pending JP2014508102A (ja) | 2010-11-15 | 2011-11-15 | アミン含有トランスフェクション試薬ならびにそれを生成および使用するための方法 |
| JP2016183855A Pending JP2017031186A (ja) | 2010-11-15 | 2016-09-21 | アミン含有トランスフェクション試薬ならびにそれを生成および使用するための方法 |
| JP2017248675A Active JP6383480B2 (ja) | 2010-11-15 | 2017-12-26 | アミン含有トランスフェクション試薬ならびにそれを生成および使用するための方法 |
| JP2018146564A Active JP6807900B2 (ja) | 2010-11-15 | 2018-08-03 | アミン含有トランスフェクション試薬ならびにそれを生成および使用するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022141466A Active JP7512335B2 (ja) | 2010-11-15 | 2022-09-06 | アミン含有トランスフェクション試薬ならびにそれを生成および使用するための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US20120136073A1 (https=) |
| EP (2) | EP3470395A1 (https=) |
| JP (6) | JP2014508102A (https=) |
| CN (3) | CN103380113B (https=) |
| BR (1) | BR122022001262B1 (https=) |
| DK (1) | DK2640700T3 (https=) |
| ES (1) | ES2702428T3 (https=) |
| WO (1) | WO2012068176A1 (https=) |
Families Citing this family (114)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1519714B1 (en) | 2002-06-28 | 2010-10-20 | Protiva Biotherapeutics Inc. | Method and apparatus for producing liposomes |
| EP1664316B1 (en) * | 2003-09-15 | 2012-08-29 | Protiva Biotherapeutics Inc. | Polyethyleneglycol-modified lipid compounds and uses thereof |
| CA2569664C (en) | 2004-06-07 | 2013-07-16 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering rna |
| CA2587411A1 (en) * | 2004-11-17 | 2006-05-26 | Protiva Biotherapeutics, Inc. | Sirna silencing of apolipoprotein b |
| CN101346393B (zh) | 2005-11-02 | 2015-07-22 | 普洛体维生物治疗公司 | 修饰的siRNA分子及其应用 |
| ES2535419T3 (es) * | 2007-12-27 | 2015-05-11 | Protiva Biotherapeutics Inc. | Silenciamiento de expresión de quinasa tipo polo usando ARN interferente |
| WO2009086558A1 (en) * | 2008-01-02 | 2009-07-09 | Tekmira Pharmaceuticals Corporation | Improved compositions and methods for the delivery of nucleic acids |
| CA2721333C (en) | 2008-04-15 | 2020-12-01 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for nucleic acid delivery |
| CA2740000C (en) | 2008-10-09 | 2017-12-12 | Tekmira Pharmaceuticals Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
| US9023820B2 (en) | 2009-01-26 | 2015-05-05 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing apolipoprotein C-III expression |
| WO2011000107A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
| US8569256B2 (en) | 2009-07-01 | 2013-10-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
| US9018187B2 (en) | 2009-07-01 | 2015-04-28 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
| US8716464B2 (en) | 2009-07-20 | 2014-05-06 | Thomas W. Geisbert | Compositions and methods for silencing Ebola virus gene expression |
| US8455455B1 (en) | 2010-03-31 | 2013-06-04 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing genes involved in hemorrhagic fever |
| US9006417B2 (en) | 2010-06-30 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
| US8466122B2 (en) | 2010-09-17 | 2013-06-18 | Protiva Biotherapeutics, Inc. | Trialkyl cationic lipids and methods of use thereof |
| CN103380113B (zh) * | 2010-11-15 | 2018-03-30 | 生命科技公司 | 含胺的转染试剂及其制备和使用方法 |
| WO2013086373A1 (en) * | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
| WO2013086354A1 (en) | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
| US9035039B2 (en) | 2011-12-22 | 2015-05-19 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing SMAD4 |
| JP6473079B2 (ja) | 2012-05-02 | 2019-02-20 | ライフ テクノロジーズ コーポレーション | 高密度増殖およびトランスフェクション培地並びに発現増強物質の固有の組み合わせを用いる、哺乳類細胞における高収率一過性発現 |
| EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| BR112016013516A8 (pt) | 2013-12-12 | 2020-05-19 | Life Technologies Corp | complexo de transfecção e seu uso para aumentar transporte de molécula de carga em células e para o tratamento de câncer e terapia gênica, bem como método in vitro para fornecer um poliânion a uma célula |
| ES2880948T3 (es) * | 2014-05-12 | 2021-11-26 | Roosterbio Inc | Células listas para imprimir y dispositivos integrados |
| US10182987B2 (en) * | 2014-05-20 | 2019-01-22 | National University Corporation Hokkaido University | Lipid membrane structure for intracellular delivery of siRNA |
| HUE060907T2 (hu) | 2014-06-25 | 2023-04-28 | Acuitas Therapeutics Inc | Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére |
| AU2016253972B2 (en) | 2015-04-27 | 2020-01-02 | Acuitas Therapeutics Inc. | Nucleoside-modified RNA for inducing an adaptive immune response |
| CN107849567B (zh) * | 2015-06-26 | 2024-07-23 | 苏州瑞博生物技术股份有限公司 | 一种siRNA、含有该siRNA的药物组合物和缀合物及它们的应用 |
| PT3313829T (pt) | 2015-06-29 | 2024-07-08 | Acuitas Therapeutics Inc | Formulações de lípidos e de nanopartículas lipídicas para a administração de ácidos nucleicos |
| KR102669726B1 (ko) | 2015-07-13 | 2024-05-29 | 라이프 테크놀로지스 코포레이션 | Cho 세포에서의 개선된 일시적 단백질 발현을 위한 시스템 및 방법 |
| CN108431224B (zh) * | 2015-09-01 | 2020-01-17 | 苏州瑞博生物技术有限公司 | 一种小干扰核酸和药物组合物及其用途 |
| JP6948313B6 (ja) | 2015-09-17 | 2022-01-14 | モデルナティエックス インコーポレイテッド | 治療剤の細胞内送達のための化合物および組成物 |
| HRP20230209T1 (hr) * | 2015-10-28 | 2023-04-14 | Acuitas Therapeutics Inc. | Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina |
| LT3394030T (lt) | 2015-12-22 | 2022-04-11 | Modernatx, Inc. | Junginiai ir kompozicijos terapinei medžiagai teikti intraceliuliniu būdu |
| EP3423438A4 (en) * | 2016-03-01 | 2020-05-06 | Molecular Transfer, Inc. | PLANT VIRUS MOTOR PROTEINS AND METHOD FOR USE THEREOF |
| US10457631B2 (en) | 2016-04-06 | 2019-10-29 | Ohio State Innovation Foundation | Biodegradable amino-ester nanomaterials for nucleic acid delivery |
| WO2017218704A1 (en) | 2016-06-14 | 2017-12-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| US12491261B2 (en) | 2016-10-26 | 2025-12-09 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| CN108220293B (zh) * | 2016-12-21 | 2021-09-24 | 苏州瑞博生物技术股份有限公司 | 一种小干扰核酸和药物组合物及其用途 |
| CN108210510B (zh) * | 2016-12-21 | 2021-04-27 | 苏州瑞博生物技术股份有限公司 | 一种小干扰核酸药物组合物及其用途 |
| CN108239643A (zh) * | 2016-12-23 | 2018-07-03 | 苏州瑞博生物技术有限公司 | 抑制人和动物中TIMP-1基因表达的siRNA、包含其的组合物及其应用 |
| CN108239644B (zh) * | 2016-12-23 | 2021-05-28 | 苏州瑞博生物技术股份有限公司 | 一种小干扰核酸和药物组合物及其用途 |
| CN108251421B (zh) * | 2016-12-28 | 2022-01-04 | 苏州瑞博生物技术股份有限公司 | 抑制人和动物中COL1A1基因表达的siRNA、包含其的组合物及其应用 |
| CN108251420B (zh) * | 2016-12-28 | 2024-08-02 | 苏州瑞博生物技术股份有限公司 | 抑制人和动物中CTGF基因表达的siRNA、包含其的组合物及其应用 |
| CN108265052B (zh) * | 2016-12-30 | 2021-05-28 | 苏州瑞博生物技术股份有限公司 | 一种小干扰核酸和药物组合物及其用途 |
| CA3049991A1 (en) | 2017-01-11 | 2018-07-19 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified rna for inducing an immune response against zika virus |
| CA3055653A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Lipid nanoparticle formulation |
| WO2018170322A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Crystal forms of amino lipids |
| EP4186888B1 (en) | 2017-03-15 | 2025-11-26 | ModernaTX, Inc. | Compound and compositions for intracellular delivery of therapeutic agents |
| WO2018191657A1 (en) | 2017-04-13 | 2018-10-18 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
| CN110799492B (zh) | 2017-04-28 | 2023-06-27 | 爱康泰生治疗公司 | 用于递送核酸的新型羰基脂质和脂质纳米颗粒制剂 |
| WO2018232120A1 (en) | 2017-06-14 | 2018-12-20 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| CA3073020A1 (en) | 2017-08-16 | 2019-02-21 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| WO2019036030A1 (en) * | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS |
| WO2019036028A1 (en) * | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS |
| EP4501322A3 (en) | 2017-08-17 | 2025-04-16 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| LT3675826T (lt) | 2017-08-31 | 2023-09-11 | Life Technologies Corporation | Katijoninės lipidų kompozicijos audiniams-specifiniam įterpimui |
| DK3719128T3 (da) | 2017-12-01 | 2025-03-03 | Suzhou Ribo Life Science Co Ltd | Dobbelt-strenget oligonukleotid, sammensætning og konjugat bestaende dobbelt-strenget oligonukleotid, fremgangsmåde herfor og anvendelse heraf |
| CA3083970A1 (en) | 2017-12-01 | 2019-06-06 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof |
| EP3719127A4 (en) | 2017-12-01 | 2021-10-20 | Suzhou Ribo Life Science Co., Ltd. | NUCLEIC ACID, COMPOSITION AND CONJUGATE WITH IT, MANUFACTURING METHOD AND USE |
| EP3719126B1 (en) | 2017-12-01 | 2025-01-01 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof |
| CN110944675B9 (zh) | 2017-12-01 | 2024-08-09 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| AU2018394875B2 (en) | 2017-12-29 | 2023-08-03 | Suzhou Ribo Life Science Co., Ltd. | Conjugates and preparation and use thereof |
| CN110283223B (zh) * | 2018-03-19 | 2022-01-04 | 广州市锐博生物科技有限公司 | 一种阳离子脂质分子及其在核酸递送中的应用 |
| WO2020038377A1 (zh) | 2018-08-21 | 2020-02-27 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的药物组合物和缀合物及其用途 |
| WO2020061367A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| IL281615B2 (en) | 2018-09-21 | 2026-01-01 | Acuitas Therapeutics Inc | Systems and methods for producing lipid nanoparticles and liposomes |
| US11896674B2 (en) | 2018-09-30 | 2024-02-13 | Suzhou Ribo Life Science Co., Ltd. | SiRNA conjugate, preparation method therefor and use thereof |
| CA3116576A1 (en) | 2018-10-18 | 2020-04-23 | Acuitas Therapeutics, Inc. | Lipids for lipid nanoparticle delivery of active agents |
| CA3119976A1 (en) | 2018-11-21 | 2020-05-28 | Translate Bio, Inc. | Cationic lipid compounds |
| WO2020135673A1 (zh) | 2018-12-28 | 2020-07-02 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| PT3908568T (pt) | 2019-01-11 | 2024-09-30 | Acuitas Therapeutics Inc | Lípidos para a administração de agentes ativos por nanopartículas lipídicas |
| PL4223886T3 (pl) | 2019-04-16 | 2025-03-31 | Genfit | Kompozycje i sposoby stabilizacji mikro-rna |
| JP7606758B2 (ja) | 2019-05-22 | 2024-12-26 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、薬物組成物及び複合体ならびに調製方法と使用 |
| KR20220011689A (ko) | 2019-05-22 | 2022-01-28 | 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 | 핵산, 약제학적 조성물, 접합체, 제조 방법, 및 용도 |
| US12590304B2 (en) | 2019-05-22 | 2026-03-31 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
| AU2020280439B2 (en) | 2019-05-22 | 2025-08-14 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
| CN111973618B (zh) * | 2019-05-23 | 2024-02-02 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与siRNA缀合物及制备方法和用途 |
| US20220315929A1 (en) | 2019-05-24 | 2022-10-06 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition and conjugate, preparation method therefor and use thereof |
| CN113795280B (zh) | 2019-05-24 | 2024-04-05 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| CN113795582B (zh) | 2019-05-24 | 2024-05-24 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| CA3155015A1 (en) | 2019-09-19 | 2021-03-25 | Modernatx, Inc. | Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents |
| AU2020350759A1 (en) | 2019-09-19 | 2022-03-31 | Modernatx, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
| CN114761376B (zh) * | 2019-12-13 | 2024-11-08 | 苏州瑞博生物技术股份有限公司 | 一种含胺转染试剂和制备方法及转染复合物 |
| JP2023517664A (ja) | 2020-03-11 | 2023-04-26 | アドバンシックス・レジンズ・アンド・ケミカルズ・リミテッド・ライアビリティ・カンパニー | 油及びガス生産のための界面活性剤 |
| WO2021255262A1 (en) | 2020-06-19 | 2021-12-23 | Sylentis Sau | siRNA AND COMPOSITIONS FOR PROPHYLACTIC AND THERAPEUTIC TREATMENT OF VIRUS DISEASES |
| ES3054438T3 (en) | 2020-07-16 | 2026-02-03 | Acuitas Therapeutics Inc | Cationic lipids for use in lipid nanoparticles |
| WO2022115645A1 (en) | 2020-11-25 | 2022-06-02 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids, and related methods of use |
| EP4015634A1 (en) | 2020-12-15 | 2022-06-22 | Sylentis, S.A.U. | Sirna and compositions for prophylactic and therapeutic treatment of virus diseases |
| EP4273245A4 (en) | 2020-12-29 | 2024-12-11 | Suzhou Ribo Life Science Co., Ltd. | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND SIRNA CONJUGATE WITH THE NUCLEIC ACID, MANUFACTURING PROCESS THEREOF AND USE THEREOF |
| WO2022241723A1 (zh) * | 2021-05-20 | 2022-11-24 | 北京理工大学 | 化合物、脂质体及其用途 |
| WO2023284763A1 (zh) | 2021-07-16 | 2023-01-19 | 苏州瑞博生物技术股份有限公司 | 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途 |
| EP4372085A4 (en) | 2021-07-16 | 2026-01-21 | Suzhou Ribo Life Science Co Ltd | Nucleic acid, composition and conjugate, container, preparation process and use |
| CN113786391B (zh) * | 2021-09-23 | 2022-07-26 | 深圳市人民医院 | 一种mRNA递送系统及其制备方法和应用 |
| CN114262275B (zh) * | 2021-12-15 | 2023-09-29 | 华中师范大学 | 一种高效低毒性dna及rna脂质递送载体 |
| CA3242402A1 (en) | 2021-12-16 | 2023-06-22 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| KR20240117104A (ko) | 2021-12-21 | 2024-07-31 | 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 | 핵산, 핵산을 포함하는 조성물 및 접합체, 이들의 제조 방법 및 용도 |
| CN114306641B (zh) * | 2022-02-17 | 2024-12-03 | 大连民族大学 | 一种胆固醇氨基衍生物-蔗糖酯型阳离子脂质体/基因复合物及其制备方法 |
| CN118434450A (zh) | 2022-04-14 | 2024-08-02 | 苏州瑞博生物技术股份有限公司 | 缀合物、含有该缀合物的药物组合物及制备方法和用途 |
| WO2023198201A1 (zh) | 2022-04-14 | 2023-10-19 | 苏州瑞博生物技术股份有限公司 | 适配体、缀合物与组合物及制备方法和用途 |
| WO2023198200A1 (zh) | 2022-04-14 | 2023-10-19 | 苏州瑞博生物技术股份有限公司 | 缀合物与组合物及制备方法和用途 |
| CA3256897A1 (en) | 2022-05-25 | 2023-11-30 | Akagera Medicines, Inc. | Lipid nanoparticles for the administration of nucleic acids and their methods of use |
| EP4642434A2 (en) | 2022-12-29 | 2025-11-05 | Life Technologies Corporation | Lipid compositions on the basis of ionizable lipids, use for delivery to immune cells |
| CN115745820B (zh) * | 2023-01-05 | 2023-04-28 | 北京悦康科创医药科技股份有限公司 | 长效低毒的新型阳离子脂质化合物及其组合物 |
| WO2024188174A1 (zh) | 2023-03-10 | 2024-09-19 | 苏州瑞博生物技术股份有限公司 | 一种药物组合物及其用途 |
| WO2025034764A1 (en) * | 2023-08-07 | 2025-02-13 | Life Technologies Corporation | Lipids for delivery of nucleic acids to eukaryotic cells |
| US12599560B2 (en) | 2023-11-02 | 2026-04-14 | Longuide Biopharma Corporation | Lipids and lipid nanoparticle formulations |
| CN117550985B (zh) * | 2023-11-08 | 2025-02-18 | 深圳厚存纳米药业有限公司 | 一种脂质化合物及其用途 |
| WO2025143892A1 (ko) * | 2023-12-29 | 2025-07-03 | 주식회사 삼양홀딩스 | 약물전달용 나노입자의 조성물 |
| CN118930449A (zh) * | 2024-07-18 | 2024-11-12 | 深圳厚存纳米药业有限公司 | 一种脂质化合物、脂质纳米粒及其制备方法和应用 |
| WO2026036019A1 (en) | 2024-08-09 | 2026-02-12 | Life Technologies Corporation | Method of producing a recombinant protein in hek-293 cells |
| CN119176819B (zh) * | 2024-11-21 | 2025-02-14 | 山东第二医科大学 | 水相中碘催化制备3,6-二氢-1,2-恶嗪衍生物的方法 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA780214A (en) | 1968-03-12 | Wean Industries | Belt wrapper | |
| US2580922A (en) | 1942-09-19 | 1952-01-01 | Nat Aluminate Corp | Prevention of foaming in steam generation |
| US2844629A (en) * | 1956-04-25 | 1958-07-22 | American Home Prod | Fatty acid amides and derivatives thereof |
| DE1129950B (de) * | 1960-06-11 | 1962-05-24 | Knoll Ag | Verfahren zur Herstellung von antimikrobiell wirksamen Derivaten des Glycinamids |
| DE1162380B (de) * | 1962-03-03 | 1964-02-06 | Knoll Ag | Verfahren zur Herstellung von antimikrobiell wirksamen Derivaten des Glycinamids |
| DE1165038B (de) * | 1962-03-03 | 1964-03-12 | Knoll Ag | Verfahren zur Herstellung von antimikrobiell wirksamen Derivaten des Glycinamids |
| CH575909A5 (https=) | 1972-08-21 | 1976-05-31 | Ciba Geigy Ag | |
| US5334761A (en) | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
| US5316948A (en) | 1992-09-04 | 1994-05-31 | Life Technologies, Inc. | N4 -methyl-2'-deoxycytidine 5'-triphosphate and its use in polymerase-catalyzed nucleic acid syntheses |
| US5578475A (en) | 1993-07-12 | 1996-11-26 | Life Technologies, Inc. | Composition and methods for transfecting eukaryotic cells |
| US5674908A (en) | 1993-12-20 | 1997-10-07 | Life Technologies, Inc. | Highly packed polycationic ammonium, sulfonium and phosphonium lipids |
| US6075012A (en) | 1994-02-11 | 2000-06-13 | Life Technologies, Inc. | Reagents for intracellular delivery of macromolecules |
| US5627159A (en) | 1994-10-27 | 1997-05-06 | Life Technologies, Inc. | Enhancement of lipid cationic transfections in the presence of serum |
| US6071890A (en) | 1994-12-09 | 2000-06-06 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy |
| EP0874910A4 (en) | 1995-06-07 | 1999-04-21 | Life Technologies Inc | ENHANCED CATIONIC LIPID TRANSFECTION BY PEPTIDES |
| US6051429A (en) | 1995-06-07 | 2000-04-18 | Life Technologies, Inc. | Peptide-enhanced cationic lipid transfections |
| US6020526A (en) | 1995-07-21 | 2000-02-01 | Genta, Incorporated | Amide-based cationic lipids |
| FR2741066B1 (fr) | 1995-11-14 | 1997-12-12 | Rhone Poulenc Rorer Sa | Nouveaux agents de transfection et leurs applications pharmaceutiques |
| DE19621871A1 (de) | 1996-05-31 | 1997-12-04 | Huels Chemische Werke Ag | Ester- und amidgruppenhaltige Polyamine sowie ein Verfahren zu ihrer Herstellung und deren Verwendung |
| CA2217550A1 (en) | 1996-10-22 | 1998-04-22 | F. Hoffmann-La Roche Ag | Cationic lipids for gene therapy |
| CA2263367A1 (fr) | 1997-06-12 | 1998-12-17 | Transgene S.A. | Nouveaux complexes lipidiques pour le transfert d'au moins une substance therapeutiquement active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique |
| KR20010031809A (ko) | 1997-11-06 | 2001-04-16 | 에프. 아. 프라저, 에른스트 알테르 (에. 알테르), 한스 페터 비틀린 (하. 페. 비틀린), 피. 랍 보프, 브이. 스펜글러, 페. 아에글러 | 디에스테르 아민 첨가물 |
| NZ512244A (en) | 1998-11-12 | 2003-12-19 | Invitrogen Corp | Polycationic transfection reagents for introducing anions into a cell |
| US6238008B1 (en) | 1999-09-08 | 2001-05-29 | Paul D. Forsythe | Wheel and tension spoke system |
| GB0031068D0 (en) | 2000-12-19 | 2001-01-31 | Smithkline Beecham Plc | Novel compounds |
| US20060009409A1 (en) | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
| ATE556714T1 (de) | 2002-02-01 | 2012-05-15 | Life Technologies Corp | Doppelsträngige oligonukleotide |
| WO2004026811A2 (en) * | 2002-09-19 | 2004-04-01 | Ciba Specialty Chemicals Holding Inc. | Succinic acid semi-amides as anti-corrosives agents |
| CA2513072A1 (en) | 2003-01-09 | 2004-07-29 | Invitrogen Corporation | Cellular delivery and activation polypeptide-nucleic acid complexes |
| WO2004105697A2 (en) | 2003-05-22 | 2004-12-09 | Molecular Transfer, Inc. | Novel lipids for transfection of nucleic acids |
| GB0502482D0 (en) | 2005-02-07 | 2005-03-16 | Glaxo Group Ltd | Novel compounds |
| US7915230B2 (en) | 2005-05-17 | 2011-03-29 | Molecular Transfer, Inc. | Reagents for transfection of eukaryotic cells |
| WO2006138380A2 (en) * | 2005-06-15 | 2006-12-28 | Massachusetts Institute Of Technology | Amine-containing lipids and uses thereof |
| US7199267B1 (en) * | 2005-10-21 | 2007-04-03 | Mediquest Therapeutics, Inc. | Recognition of oligiosaccaride molecular targets by polycationic small molecule inhibitors and treatment of immunological disorders and infectious diseases |
| EP2004141A2 (en) | 2006-03-17 | 2008-12-24 | Novosom AG | An efficient method for loading amphoteric liposomes with nucleic acid active substances |
| NZ593080A (en) | 2006-05-05 | 2012-12-21 | Molecular Transfer Inc | Novel reagents for transfection of eukaryotic cells |
| CA2927045A1 (en) * | 2006-10-03 | 2008-04-10 | Muthiah Manoharan | Lipid containing formulations |
| EP2195428B1 (en) | 2007-09-19 | 2013-12-11 | Applied Biosystems, LLC | SiRNA SEQUENCE-INDEPENDENT MODIFICATION FORMATS FOR REDUCING OFF-TARGET PHENOTYPIC EFFECTS IN RNAi, AND STABILIZED FORMS THEREOF |
| WO2009046220A2 (en) * | 2007-10-02 | 2009-04-09 | Mdrna, Inc. | Lipopeptides for delivery of nucleic acids |
| WO2009086558A1 (en) | 2008-01-02 | 2009-07-09 | Tekmira Pharmaceuticals Corporation | Improved compositions and methods for the delivery of nucleic acids |
| WO2009148955A2 (en) * | 2008-05-29 | 2009-12-10 | Mdrna, Inc | Multi-arm amines and uses thereof |
| MX360460B (es) | 2008-10-20 | 2018-11-05 | Alnylam Pharmaceuticals Inc | Composiciones y metodos para inhibir la expresion de transtiretina. |
| WO2010062322A2 (en) * | 2008-10-27 | 2010-06-03 | Massachusetts Institute Of Technology | Modulation of the immune response |
| EP3269395A1 (en) | 2008-11-07 | 2018-01-17 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
| CN111808084A (zh) * | 2008-11-10 | 2020-10-23 | 阿布特斯生物制药公司 | 用于递送治疗剂的新型脂质和组合物 |
| US8460696B2 (en) | 2009-03-20 | 2013-06-11 | Egen, Inc. | Polyamine derivatives |
| JP5894913B2 (ja) | 2009-06-15 | 2016-03-30 | アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｐｃｓｋ９遺伝子を標的とする、脂質で製剤化されたｄｓｒｎａ |
| US8569256B2 (en) * | 2009-07-01 | 2013-10-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
| US8466122B2 (en) * | 2010-09-17 | 2013-06-18 | Protiva Biotherapeutics, Inc. | Trialkyl cationic lipids and methods of use thereof |
| CN103380113B (zh) | 2010-11-15 | 2018-03-30 | 生命科技公司 | 含胺的转染试剂及其制备和使用方法 |
| US9011903B2 (en) * | 2011-06-08 | 2015-04-21 | Nitto Denko Corporation | Cationic lipids for therapeutic agent delivery formulations |
-
2011
- 2011-11-15 CN CN201180060664.1A patent/CN103380113B/zh active Active
- 2011-11-15 CN CN202110421347.3A patent/CN113214102A/zh active Pending
- 2011-11-15 ES ES11793580T patent/ES2702428T3/es active Active
- 2011-11-15 DK DK11793580.9T patent/DK2640700T3/en active
- 2011-11-15 EP EP18202571.8A patent/EP3470395A1/en active Pending
- 2011-11-15 CN CN201810144659.2A patent/CN108358812B/zh active Active
- 2011-11-15 WO PCT/US2011/060877 patent/WO2012068176A1/en not_active Ceased
- 2011-11-15 JP JP2013539959A patent/JP2014508102A/ja active Pending
- 2011-11-15 BR BR122022001262-0A patent/BR122022001262B1/pt active IP Right Grant
- 2011-11-15 US US13/297,231 patent/US20120136073A1/en not_active Abandoned
- 2011-11-15 EP EP11793580.9A patent/EP2640700B1/en active Active
-
2014
- 2014-07-24 US US14/340,395 patent/US9901642B2/en active Active
-
2016
- 2016-09-21 JP JP2016183855A patent/JP2017031186A/ja active Pending
-
2017
- 2017-12-15 US US15/844,380 patent/US10406237B2/en active Active
- 2017-12-26 JP JP2017248675A patent/JP6383480B2/ja active Active
-
2018
- 2018-08-03 JP JP2018146564A patent/JP6807900B2/ja active Active
-
2019
- 2019-08-30 US US16/557,967 patent/US11464863B2/en active Active
-
2020
- 2020-12-08 JP JP2020203413A patent/JP7138692B2/ja active Active
-
2022
- 2022-08-19 US US17/821,122 patent/US12458700B2/en active Active
- 2022-09-06 JP JP2022141466A patent/JP7512335B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021059555A5 (https=) | ||
| JP2022184875A5 (https=) | ||
| Hirko et al. | Cationic lipid vectors for plasmid DNA delivery | |
| Montier et al. | Progress in cationic lipid-mediated gene transfection: a series of bio-inspired lipids as an example | |
| Niculescu-Duvaz et al. | Structure-activity relationship in cationic lipid mediated gene transfection | |
| US9415109B2 (en) | Stable non-aggregating nucleic acid lipid particle formulations | |
| US10626393B2 (en) | Delivering CRISPR therapeutics with lipid nanoparticles | |
| JP2011507534A5 (https=) | ||
| Draghici et al. | Synthetic nucleic acid delivery systems: present and perspectives | |
| JP6192061B2 (ja) | 中性脂質を含む両性リポソーム | |
| EP1328254B1 (en) | Lipid formulations for target delivery | |
| US20130216607A1 (en) | Zwitterionic lipids | |
| JP7774615B2 (ja) | 大型ｒｎａの脂質ナノ粒子封入 | |
| WO2011056682A1 (en) | Reverse head group lipids, lipid particle compositions comprising reverse headgroup lipids, and methods for the delivery of nucleic acids | |
| WO2017019891A2 (en) | Compositions and methods for silencing hepatitis b virus gene expression | |
| JP2017014253A (ja) | トランスフェクションエンハンサー要素を含む脂質および脂質集合体 | |
| US6649780B1 (en) | Cationic lipids | |
| JP2024541924A5 (https=) | ||
| AU2001254548A1 (en) | Enhanced stabilised plasmid-lipid particle-mediated transfection using endosomal membrane | |
| WO2001080900A2 (en) | Enhanced stabilised plasmid-lipid particle-mediated transfection using endosomal membrane | |
| US20080145413A1 (en) | Lipids and lipid assemblies comprising transfection enhancer elements | |
| Koynova et al. | Recent patents in cationic lipid carriers for delivery of nucleic acids | |
| JP2024534066A5 (https=) | ||
| WO2024211865A2 (en) | Lipids and lipid-like compounds for therapeutic lipid nanoparticle (lnp) delivery | |
| WO2024211625A1 (en) | Hbv gene editing |